Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
13 Limonene Chiu-wing Lam, Ph.D., D.A.B.T. Toxicology Group Habitability and Environmental Factors Division Johnson Space Center National Aeronautics and Space Administration Houston, Texas PHYSICAL AND CHEMICAL PROPERTIES Synonym: 1-Methyl-4-(1-methylethenyl) cyclohexene; p-mentha-1,8-diene; en- thadiene; carvene; cinene; citrus ter- penes; and orange oil terpenes (NICNAS 2002) CAS number: 5989-27-5 Molecular weight: 136.24 Boiling point: 176Â°C Density: 0.84 Vapor pressure: <3 mm Hg at 14Â°C Solubility in water: Sparingly soluble (13.8 mg/L at 25Â°C) Concentration conversion: 1 ppm = 5.6 mg/mÂ³, 1 mg/mÂ³ = 0.18 ppm OCCURRENCE AND USE Natural Occurrence and Commercial Uses Limonene, chemically belonging to the terpene family and bearing an asymmetric carbon atom, exists in two enantiomers, l-limonene [also referred to as (â)-limonene or S-(â)-limonene] and d-limonene [also referred to as (+)- limonene or R-(+)-limonene]. l-Limonene has a piney and turpentine smell, whereas d-limonene has a pleasant lemon-like fragrance and a fresh citrus taste. The former monoterpene is present in pine oils and some trees; the latter is pre- 250
Limonene 251 sent in lemon, orange, other citrus fruits, and to a lesser extent in vegetables and plants. d-Limonene is the major constituent of lemon and orange oils; it is also present in other essential oils. Besides being naturally present in fruits, vegeta- bles, and their products (such as orange juice, which contains 100 ppm of d- limonene), it is used as a flavoring agent and is found in common food items, such as ice cream (68 ppm), baked goods (120 ppm), gelatins and puddings (48 to 400 ppm), and nonalcoholic beverages (31 ppm) (NTP 1990, NICNAS 2002). d-Limonene is a food additive on the Food and Drug Administrationâs Generally Recognized as Safe List (Opdyke 1978). Consumption of d-limonene has been estimated to be 0.2 to 2 mg/kg body weight per day (or 14 to 140 mg/70 kg/d) (IARC 1999). Because d-limonene can be isolated from a large number of natu- ral sources and has a desirable odor and taste, it is the isomer that is commer- cially produced and is mainly used in soap, personal hygiene products, medici- nal cosmetics, and perfume, in addition to its wide use in foods and beverages. In 1976, 68,000 kg of d-limonene was produced and used in the United States mainly as a fragrance and flavoring agent; by 1984, the consumption increased to 254,000 kg. The use of limonene has continued to increase because consum- ers prefer natural and organic food additives to synthetic products. d-Limonene seems to have some medicinal properties. It has been shown experimentally to have protective effects against certain types of cancer and was evaluated in phase I clinical trials with advanced cancer patients (Gould 1997). Because it has good solvent properties, relatively low toxicity, and a pleasant odor, d-limonene is used increasingly as an industrial solvent to replace chlorinated hydrocarbons as a remover/stripper for wax, paints, ink, and adhe- sives and in degreasing operations and other applications (NICNAS 2002). It has been substituted for xylene in slide preparation in many histopathology laborato- ries. Because of its widespread presence in botanical and commercial products and its increasing industrial uses, d-limonene is released into the environment from biogenic and anthropogenic sources (NICNAS 2002). Occurrence and Use in Spacecraft d-Limonene has been considered for use on the International Space Station (ISS) as a cleansing solvent. On the ISS, low-toxicity water-soluble solvents (especially alcohols such as ethanol and isopropanol) are used in medical appli- cations and for hardware cleansing. These volatile, highly soluble, and low- molecular-weight compounds, which are released into the ISS air after their use, are readily removed together with water vapor by the humidity removal system as water condensate. In the ISS water purification system, the contaminants in the condensate are removed by charcoal filtration and catalytic oxidation. This water recycling system has a limited capacity for removing these water-borne organics. Thus, the ISS program has placed a restriction on the use of water- soluble volatile organic compounds (VOCs).
252 SMACs for Selected Airborne Contaminants d-Limonene, a compound with low solubility in water and relatively low toxicity, has been proposed as a cleansing agent to reduce the use of alcohols and other water-soluble VOCs on the ISS. Replacing these compounds with the water-insoluble terpene would increase d-limonene concentration in the ISS atmosphere. Increased industrial applications of d-limonene would increase its presence in nonmetallic materials as well as increase the potential for off- gassing of limonene into the ISS atmosphere if some of these materials are used for construction of ISS components or flight hardware. Limonene has been commonly and constantly found in the ISS atmosphere. ISS air samples col- lected in 2003 showed limonene concentrations ranging from 0.036 to 0.13 mg/m3 (JSC 2003); this range is similar to that (0.035 to 0.18 mg/m3) found in the samples collected more recently (JSC 2008). The variation in limonene con- centrations in the samples collected at different times during the same ISS mis- sion increment probably reflects the extent the air was circulated through the activated charcoal bed in the ISS trace contaminant removal system. This document has been drafted to set the airborne exposure limits of d- limonene on the ISS and should also provide the data needed for deciding whether to increase d-limonene uses as a degreaser or cleaner associated with space mission operations. TOXICOKINETICS AND METABOLISM Absorption, Distribution, and Excretion d-Limonene, a small lipophilic compound, has high blood/air, oil/water, and oil/blood partition coefficients (Î»blood/air = 42, Î»oil/water = 3,167, Î»oil/blood = 140) (Falk et al. 1990); it is expected to be taken up readily from the lungs and from the gastrointestinal tract. The toxicokinetics of d-limonene were studied in a group of eight human volunteers engaged in light exercise and exposed for 2 h to the vapor at 10, 225, and 450 mg/m3 (corresponding to ~2, 40, and 80 ppm) (Falk-Filipsson et al. 1993). The average pulmonary uptake of the vapor was 65%, 68%, and 68%, respectively. Measurements obtained in subjects exposed to d-limonene at 450 mg/m3 showed that ~1% of the total uptake was eliminated unchanged in expired air after exposure ended, whereas ~0.003% was elimi- nated unchanged in the urine. The finding that very little of the compound was excreted unchanged in breath and urine indicates that the compound is exten- sively metabolized or avidly taken up by fat. The half-lives of the triphasic elimination of limonene from blood were 3, 30, and 750 min (Falk-Filipsson et al. 1993). When humans and laboratory animals (rat, guinea pig, hamster, rabbit, and dog) were given oral doses of d-[14C]limonene (which was completely ab- sorbed), 75% to 95% of the radioactivity was recovered in urine within 2 or 3 d after they ingested the compound. Most of the radioactivity was recovered in the first 24 h; less than 10% was found in feces (Kodama et al. 1976). After admini- stration of radiolabeled d-limonene orally to male Wistar rats, Igimi et al. (1974)
Limonene 253 found that radioactivity in the blood reached a maximum 2 h after the treatment. The blood concentrations remained relatively high for 10 h and then declined. A negligible amount of radioactivity was found in the blood 48 h post-treatment. Study of the distribution of radioactivity in the tissues of these rats showed that the liver had the highest concentration, followed by the kidneys and blood (fat was not examined). Autoradiograms also showed that negligible radioactivity remained in the body 48 h after ingestion of d-[14C]limonene. These results show that only small amounts of limonene or its metabolites accumulate in the body. The recovery of radioactivity in urine, feces, and breath (as CO2) was 60%, 5%, and 2%, respectively (Igimi et al. 1974). Metabolism The finding that only small amounts of absorbed airborne limonene were eliminated in the urine (0.003%) and breath (~1%) of exposed humans indicates that the compound was extensively metabolized (Falk-Filipsson et al. 1993). As mentioned above, in humans and laboratory animals given d-[14C]limonene, 75% to 95% of the radioactivity was recovered in urine within 2 or 3 d, with most recovered in the first 24 h after dosing (Kodama et al. 1976). Depending on the animal species, the metabolism of limonene could occur by hydroxylation (or epoxidation followed by hydroxylation) of the ethenyl group, hydroxylation of the cyclohexene ring, and/or oxidation of the 1-methyl group. Most of these metabolites are further conjugated by phase II enzymes before they are elimi- nated in the urine (Igimi et al. 1974, Kodama et al. 1976). Kodama et al. (1976) proposed the metabolic pathway shown in Figure 13-1 based on the information of the metabolites they identified (Table 13-1). In the two human test subjects, about 30% of the administered dose was found in the urine as d-limonene-8,9- diol and its glucuronide; about 10% was identified as perillic acid (M-III; Figure 1). In cancer patients who received oral d-limonene therapy for up to 1 year, the major urinary metabolites were glucuronide conjugates of perillic acid, dihy- droperillic acid, limonene-8,9-diol, and monohydroxylimonene (Vigushin et al. 1998). In male rats, some of the d-limonene-1,2-epoxide produced was bound reversibly to 2u-globulin, a protein produced exclusively by the livers of these rodents (Lehman-McKeeman et al. 1989). TOXICITY SUMMARY With its pleasant odor and taste, d-limonene dwarfs its levorotary isomer in industrial production and commercial uses. Toxicity studies on limonene have been conducted almost exclusively on the former compound. d-Limonene is ubiquitous in fruits and vegetables; it is a food additive on the Food and Drug Administrationâs approved list (Opdyke 1978). This natural flavoring agent has low irritancy and toxicity (Falk-Filipsson et al. 1993). For these reasons, very
254 SMACs for Selected Airborne Contaminants FIGURE 13-1 Major Pathways for d-Limonene Metabolism. Source: Kodama et al. 1976. Reprinted with permission; copyright 1976, Xenobiotica. few inhalation studies have been conducted to assess the toxicity of this com- pound. A 2-year carcinogenesis bioassay conducted by the National Toxicology Program (NTP 1990) on rodents gavaged with doses of d-limonene up to 1,000 mg/kg/d showed no histopathology in female rats or both sexes of mice, but kidney lesions and neoplasms were found in male rats (Table 13-2). The lesions were found to be associated with hyaline droplets, which contained Î±2u-globulin. Because the formation of Î±2u-globulin in the liver is unique to the male rat and does not occur in humans, and because this protein played a crucial role in the pathogenesis and carcinogenesis of d-limonene, the results for kidney cancer and lesions in these animals are not considered relevant to assessment of the risk to humans of d-limonene exposure (IARC 1999). Table 13-3 summarizes the inhalation toxicity of d-Limonene, while the data on oral toxicity of this com- pound are summarized in Table 13-4 and 13-5. Acute and Short-Term Toxicity Studies Human Exposures In a study to investigate the pulmonary uptake of inhaled d-limonene in humans (mentioned above), eight test subjects were exposed for 2 h on three occasions at concentrations of approximately 10, 225, and 450 mg/mÂ³ (about 2, 40, or 80 ppm) (Falk-Filipsson et al. 1993). The subjects did not have any irrita- tion or symptoms related to the central nervous system. A slight (~ 2%), but
TABLE 13-1 Metabolites in Urine Species in Which Metabolites Have Been Detected Numbera Limonene Metabolites Rat Guinea Pig Hamster Rabbit Dog Human M-I p-Mentha-1,8-dien-10-ol â X X X X X M-II p-Mentha-1-ene-8,9-diol X X X X X* X M-III Perillic acid X X X X X X M-IV Perillic acid-8,9-diol X* X X X* X X M-V p-Mentha-1,8-dien-10-yl-Î²-D-glucopyranosiduronic X X X X X X acid M-VI 8-Hydroxy-p-menth-1-en-9-yl-Î²-D- X X* X X X X* glucopyranosiduronic acid M-VII 2-Hydroxy-p-menth-8-en-7-oic acid X X X X X X M-VIII Perillylglycine X X X X X X M-IX Perillyl-Î²-D-glucopyranosiduronic acid X X X* X X X M-X p-menth-1-ene-6,8,9-triol X X X X X â M-XI p-Mentha-1,8-dien-6-ol X X X X X X a Reference to structures shown in Figure 13-1. Abbreviations: *, major metabolite; â, metabolite not found; X, metabolite found. Source: Kodama et al. 1976. Reprinted with permission; copyright 1976, Xenobiotica. 255
256 SMACs for Selected Airborne Contaminants statistically significant (p < 0.01), decrease in vital capacity measurement was noted after an exposure to d-limonene at the highest concentration, but no clini- cal symptoms were observed in the test subjects. The exposure duration was very short (total of 6 h) and was unlikely to produce lung lesions that could pro- duce pulmonary restriction reflected clinically as reduction in vital capacity. The assessment that d-limonene is very unlikely to elicit lung lesions after such a short time is supported by the results of other lung function tests, including forced expiratory volumes after 1 second, residual volume, total lung capacity, peak expiratory flow, mean expiratory flow, airway resistance, and airway con- ductance, which showed no significant changes after the d-limonene exposure. Although it was statistically significant, the authors concluded that the 2% change in vital capacity had no functional significance. The decrease in forced vital capacity was not consistent with the absence of change in total lung capac- ity and airway conductance, which are two more reliable measures of restriction. In a study to assess eye irritancy and odor threshold of VOCs, including l- limonene, released by Nordic coniferous trees that produce the characteristic wood odor (when the wood is used for building), 12 volunteers were exposed to four monoterpenes separately (Molhave et al. 2000). With goggle instrumenta- tion, l-limonene was administered to the eyes for 2 min and the threshold of irri- tation was found to be 3,400 mg/mÂ³ (600 ppm). The odor threshold was found to be 12 mg/mÂ³. d-Limonene had been tested for toxicity to determine the maximum toler- ated doses in cancer patients before it was used as a therapeutic agent to sup- press cancer growth on these patients. Thirty-two patients were given d- limonene ranging from 0.5 to 12 g/d/m2 of body surface for 21 d or more; some were dosed for up to 1 year. The maximum tolerated dose was 8 g/d/m2 or about 190 mg/kg/d. The toxicities were limited to gastrointestinal effects (nausea, vomiting, and diarrhea) in a dose-dependent fashion. Vigushin et al. (1998) con- cluded that d-limonene had low toxicity. In another study, therapeutic admini- stration of 20 g of d-limonene orally to patients with gallstones resulted in diar- rhea and painful contractions, but no changes in blood biochemical parameters (Igimi et al. 1976). TABLE 13-2 Incidence of Kidney Lesions, Including Cancer, in Male Rats Dosed Orally with d-Limonene for 2 Yearsa Lesions 0 mg/kg/d 75 mg/kg/d 150 mg/kg/d Papilla mineralization 7/50 43/50 48/50 Papilla epithelial 0/50 35/50 43/50 hyperplasia Tubular cell hyperplasia 0/50 4/50 7/50 Tubular cell adenoma 0/50 4/50 8/50 Tubular cell 0/50 4/50 3/50 adenocarcinoma a d-Limonene in corn oil was administered by gavage 5 days per week.
Limonene 257 TABLE 13-3 Inhalation Toxicity of d-Limonene Exposure Dose, PPM Duration Species Effects Reference Human studies 610a 2 min Human Threshold of Molhave et al. (n = 12) eye irritation 2000 2, 40, or 80 2h Human No irritation Falk-Filipsson (n = 8) No CNS effects et al. 1993 No changes in pulmonary function Animal studies â¤2,421a 30 min BALB/ca No pulmonary Larsen et al. mouse (n = 4) irritation 2000 detected â¤1,600 30 min BALB/ca No pulmonary Larsen et al. mouse (n = 4) irritation 2000 detected 1,715a 30 min BALB/ca RD50b Larsen et al. mouse (n = 4) 2000 1,163 30 min BALB/ca RD50 Larsen et al. mouse (n = 4) 2000 199a 30 min BALB/ca RD0c Larsen et al. mouse (n = 4) 2000 125 30 min BALB/ca RD0 Larsen et al. mouse (n = 4) 2000 111 10-30 min BALB/ca Respiratory rate Wolkoff et al. mouse (n = 4) depression not 2000 detected 47 1h BALB/ca No effects on Rohr et al. 2002 mouse (n = 4) respiratory system a Study conducted on l-limonene. b RD50, respirable rate depression by 50% due to pulmonary irritation in the exposed ani- mals. c RD0, no-observed-effect level for respirable irritation in the exposed animals. TABLE 13-4 Oral Toxicity of d-Limonene in Rodents Dosage, Exposure mg/kg/d Durationa Speciesb Effects 6,000 16 d 10 rats, 10 mice 10/10 rats died, 10/20 mice died 3,000 16 d 10 rats, 10 mice 2/10 rats died, 1/20 mice died 1,650 16 d 10 rats, 10 mice No deaths; decrease in body weight gain 825 16 d 10 rats, 10 mice No observable effects (no histologic exam) 413 16 d 10 rats, 10 mice No observable effects (no histologic exam) c 75-1,200 21 d 24 rats Dose-related granules, contained Î±2u-globulin (12 M, 12 F) in kidneys of male rats (Continued)
258 SMACs for Selected Airborne Contaminants TABLE 13-4 Continued Dosage, Exposure mg/kg/d Durationa Speciesb Effects 2,400 13 wk 20 rats 14/20 died; lethargy, excessive lacrimation (10 M, 10 F) nephropathy (in male rats only) 2,000 13 wk 20 mice 3/20 died; lethargy, excessive lacrimation (10 M, 10 F) nephropathy (in male rats only) 1,200 13 wk 20 rats Rough hair coats, decreased activity, lethargy, (10 M, 10 F) excessive lacrimation nephropathy (in male rats only) 1,000 13 wk 20 mice Rough hair coats and decreased activity (10 M, 10 F) 600 13 wk 20 rats Nephropathy (in male rats only) (10 M, 10 F) 500 13 wk 20 mice None (10 M, 10 F) 300 13 wk 20 rats Effects (nephropathy) only in male rats (10 M, 10 F) 250 13 wk 20 mice None (10 M, 10 F) 150 13 wk 20 rats Effects (nephropathy) only in male rats (10 M, 10 F) 125 13 wk 20 mice None (10 M, 10 F) 1,000 2y 50 mice (F) 10% less body weight gain, no other effects 500 2y 50 mice (F) No effects, decrease in incidence of cytomegaly and multinucleated cells in liver 500 2y 50 mice (M) Increase in incidence of cytomegaly and multinucleated cells in liver 250 2y 50 mice (M) Decrease in incidence of cytomegaly and multinucleated cells in liver 600 2y 50 rats (F) 5% less body weight gain, no other effects 300 2y 50 rats (F) No effects 150 2y 50 rats (M) 5% less body weight gain, decrease in survival, renal lesions and tumorsc,d 75 2y 50 rats (M) Decrease in survival, renal lesions and tumorsc,d a Daily doses given by gavage 5 d per week. b All these NTP studies used Fischer 344 rats and B6C3F1 mice. c Doses: 75, 150, 300, 600, and 1200 mg/kg/d. d See details in Table 13-2. Abbreviations: M, male; F, female. Source: NTP 1990.
Limonene 259 TABLE 13-5 Oral Toxicity of d-Limonene (Non-NTP Studies) Dose, Exposure mg/kg/d Duration Species Effects Reference 1,000 6 mo Dog No hyaline droplets or Webb et al. 1990 (5 M, 5 F) kidney lesions, kidney weight ca. 30% higher than controls 100 6 mo Dog No hyaline droplets or Webb et al. 1990 (5 M, 5 F) kidney lesions 2,363 Gestation 15 mice â maternal body weight Kodama et al. 1977a days 7-12 â fetal skeletal abnormality 591 Gestation 15 mice No effects in dams Kodama et al. 1977a days 7-12 and fetuses 1,000 Gestation 10-18 Some fetuses died Kodama et al. 1977b days 6-18 rabbits â maternal body weight 500 Gestation 10-18 Some fetuses died Kodama et al. 1977b days 6-18 rabbits â maternal body weight 250 Gestation 10-18 No effects in dams Kodama et al. 1977b days 6-18 rabbits and fetuses Abbreviations: M, male; F, female. Animal Exposures Effects of d-limonene on sensory irritation, pulmonary irritation, and expi- ratory airflow limitation were investigated in mice; the results showed that an exposure to 47 ppm of limonene for 1 h produced no measurable changes. Wolkoff et al. (2000) reported that, in BALB/c mice exposed to 111 ppm for 30 min, sensory irritation did not occur. Larsen et al. (2000) conducted a study on d-limonene and its enantiomer l-limonene by monitoring respiratory rate, tidal volume, and mid-expiratory flow rate of mice exposed to the compounds for 30 min. Pulmonary irritation and bronchoconstriction were not observed at concen- trations â¤ 1,600 ppm for d-limonene and â¤ 2,421 ppm for l- limonene. The con- centration that decreased respiratory rate by 50% (RD50) in a 30-min exposure was estimated to be 1,163 ppm for d-limonene and 1,715 ppm for l-limonene; the no-observed-effect levels for sensory irritancy for these two limonene com- pounds were estimated to be 125 and 199 ppm, respectively. In a dose-finding study on d-limonene for a subsequent NTP carcinogene- sis bioassay, groups of 10 Fisher 344 rats and 10 B6C3F1 mice (5 of each sex) were gavaged with the compound (in corn oil) at 413, 825, 1,650, 3,000, or 6,600 mg/kg/d for 16 d (5d/wk). In the groups that received 3,300 or 6,600 mg/kg/d, 18 rats and 19 mice died. Body weight gain decreased at 1,650 mg/kg/d. No compound-related signs of toxicity were observed in animals ad- ministered <1,650 mg/kg/d (NTP 1990).
260 SMACs for Selected Airborne Contaminants Long-Term Toxicity Studies Long-term human exposures to limonene have not been reported. In an NTP 13-wk (5 d/wk) study, groups of 20 rats (10 males, 10 females) were ga- vaged with d-limonene at 0, 150, 300, 600, 1,200, or 2,400 mg/kg/d; groups of 20 mice (10 males, 10 females) were dosed at 0, 125, 250, 500, 1,000, or 2,000 mg/kg/d. In the 2,400-mg/kg groups, 14 rats died; in the 2,000-mg/kg groups, 3 mice died. Body weight gain decreased in a dose-related fashion in the male rats starting at 600 mg/kg/d; in male mice, the decrease was observed in the 1,000- and 2,000-mg/kg groups. Male rats administered 1,200 or 2,400 mg/kg/d showed lethargy and excessive lacrimation; lethargy was also observed in male mice treated with the two highest doses (1,000 and 2,000 mg/kg/d). The only compound-related pathologic effect noted was nephropathy in male rats (NTP 1990). Kanerva et al. (1987) initiated a study to investigate the time and dose re- lationship of limonene-induced renal lesions, specifically hyaline droplet forma- tion. Groups of five F344 male rats were given (by gavage) d-limonene at 75, 150, or 300 mg/kg/d for up to 4 wk (5 d/wk). The animals were killed at the end of the 1st or 4th week; at these times, an increase in liver weight was noted in the highest dose group. The increase in number of protein droplets in the kid- neys of rats was dose dependent. Formation of granular casts and chronic nephrosis were found only in the rats that received 4 wk of limonene treatment. The nephropathy was found to associate with Î±2u-globulin in the kidney. In an effort to assess whether nephropathy is unique to male rats, Webb et al. (1990) dosed groups of 10 dogs (5 males, 5 females) with d-limonene at 0, 100, or 1,000 mg/kg/d; the dose was divided and given by gavage twice daily for 6 months. The body weights of the animals were not affected. In the 1,000- mg/kg/d group, the average kidney weight of the female dogs and the absolute kidney weight of male and female dogs were all about 30% higher than that of the controls. The 100-mg/kg/d group showed no effects on kidney weight. Mi- croscopic examination of the kidneys revealed no hyaline droplet nephropathy or other lesions associated with the d-limonene treatment. The authors did not explain or speculate about the reasons for the kidney weight increase in the high-dose group but did point out that this high dose âis more than 10 times higher than that causes frank nephrotoxicity and significant increase in renal cancer in male rats (70 mg/kg body weight, National Toxicology Program, 1990).â After completing its 13-wk study, NTP (1990) conducted a 2-year car- cinogenesis study in which groups of 50 male rats were gavaged daily (5 d/wk) with d-limonene at 0, 75, or 150 mg/kg; female rats were dosed with the com- pound at 0, 300, or 600 mg/kg. The doses for groups of male mice were 0, 250, and 500 mg and those for female mice were 0, 500, and 1,000 mg/kg. Female mice exposed to the highest dose had 5% to 15% lower mean body weights
Limonene 261 than their respective vehicle controls after week 28 of the study; no other com- pound-related clinical signs of toxicity were noted in either sex. The survival of the female rats administered 600 mg/kg was significantly lower than that of the vehicle controls. Compared with controls (8/49), the incidence of multinucleated cells in the livers of male mice was lower in the 250-mg/kg group (4/36) but higher in the 600-mg/kg group (32/50). The incidence of hepatic cytomegaly in these three groups of male mice followed the same pattern, with corresponding rates of 23/49, 11/36, and 38/50. No differences from controls were observed in treated female mice. Similar to the findings of the NTP (1990) 13-wk study that histopathologic lesions in male rats treated with d-limonene were found exclusively in the kid- ney, results of the 2-year toxicology and carcinogenesis studies revealed kidney lesions in male rats, which were the only compound-related histopathology noted. In both dosage groups, pathologic manifestations in the male rats were deposition of mineral in the renal medulla and papilla and hyperplasia of the transitional epithelium of the papilla. Uncommon tubular cell adenomas and adenocarcinomas of the kidney were also observed in some of the rats chroni- cally dosed with 75 or 150 mg/kg/d. Tubular cell hyperplasia and neoplasia were observed at increased incidences with positive trends in dosed male rats, which are shown in Table 13-2. Tubular cell hyperplasia, adenomas, and adenocarci- nomas were part of a continuous morphologic spectrum. Hyperplasia is a prolif- erative lesion characterized by enlarged renal tubules with stratification of the tubular epithelium. Tubular cell adenomas are characterized by enlarged tubules and with proliferative epithelial cellular mass up to 1 cm in diameter. Adenomas consisted of relatively well-differential epithelium and exhibited solid, cystic, or papillary patterns of growth. Adenocarcinomas showed growth patterns similar to those in adenomas but generally were larger and exhibited cellular pleomor- phism and anaplasia. Carcinogenicity As mentioned above, NTP conducted a 2-year bioassay in F344 rats (50 rats per sex per dose) and B6C3F1 mice gavaged with d-limonene. Doses as high as 500 mg/kg/d in female rats and 1,000 mg/kg/d in male and female mice did not increase cancer incidences in these rodents. The incidence of neoplasms of the anterior pituitary gland in high-dose female mice was lower than that in the vehicle-control mice (adenomas and carcinomas combined: vehicle control, 12/49; high dose, 2/48). These results are consistent with tumor suppression activity of d-limonene observed by others (Crowell et al. 1994). However, male rats dosed with 75 or 150 mg/kg/d had uncommon forms of tubular cell adeno- mas and adenocarcinomas of the kidney, which are summarized in Table 13-2. No chemical-related increases in other forms of cancer were observed.
262 SMACs for Selected Airborne Contaminants Mechanism of Limonene-Induced Renal Pathogenesis and Carcinogenesis in Male Rats, and the Irrelevancy of the Renal Lesions of These Animals for Assessment of Human Risk from Limonene Exposures Several studies were launched to investigate the mechanism of pathogenesis after NTP found that limonene caused kidney cancer and other renal lesions in male rats. One of these studies was conducted by NTP (1990), in which male and female F344/N rats were administered d-limonene at 75 to 1,200 mg/kg for 21 d. Microscopic examination of kidney sections from these rats indicated a compound-related increase in intracytoplasmic granules in the proximal convoluted tubules of dosed male rats but not of female rats. Immuno- histochemical staining of the kidney tissue revealed that the granules contained Î±2u-globulin. An enzyme-linked immunosorbent assay also showed that the amount of Î±2u-globulin increased in kidney homogenates from d-limonene- dosed male rats. These results established the links between the male unique Î±2u-globulin and nephropathy. Tsuji et al. (1975) investigated nephrotoxicity of d-limonene in another strain of rats. Male and female Sprague-Dawley rats were gavaged with d- limonene at 277, 554, or 1,385 mg/kg/d daily for 6 months. Like that in the re- sults with F344 rats in the NTP study, nephropathy was observed in the male but not in the female rats similarly exposed. The kidney lesions also consisted of granular casts characteristic of Î±2u-globulin. The association of d-limonene with Î±2u-globulin in the kidney of exposed rats was investigated in a study in which Sprague-Dawley rats were exposed to radiolabeled d-limonene (Lehman-McKeeman et al. 1989). About 40% and 5% of the radioactivity found in the kidneys of males and females, respectively, bound to proteins. The kidney protein that contained the radioactivity in male rats was identified as Î±2u-globulin, and 82% of the radiolabeled moiety was as- sociated with d-limonene-1,2-epoxide. No Î±2u-globulin-radiolabeled complex was detected in kidneys of d-limonene-exposed female rats. Î±2u-Globulin is synthesized under androgenic control in the liver of mature male rats, secreted into the blood, and excreted in large amounts in urine. This small-molecular-weight protein is found in minute quantities in female rats. In the acute stage of male-rat-specific and chemical-induced nephropathy, accumulations of protein droplets (consisting chiefly of Î±2u-globulin) were found in the lysosomes of cells in the P2 segment of the proximal convoluted tubules. As discussed above, in male rats, d-limonene-1,2-epoxide binds re- versibly to this protein (Lehman-McKeeman et al. 1989). The Î±2u-globulin bound to d-limonene-1,2-epoxide resists degradation by lysosomal enzymes, resulting in an accumulation of Î±2u-globulin-limonene-derived complex. The accumulated protein complex caused tubular cell degeneration and necrosis with some degree of cell regeneration (Saito et al. 1991). d-Limonene pathogenesis in the kidneys of male rats was further investi- gated by Dietrich and Swenberg (1991), who used male F344 rats and Î±2u-
Limonene 263 globulin-deficient NCI-NBR rats. The rats, pretreated with 0 or 500 ppm of a preneoplastic initiator (N-ethyl-N-hydroxyethylnitrosamine) in drinking water for 2 wk, were gavaged with d-limonene at 0 or 150 mg/kg/d for 30 wk (5 d/wk). A 5-fold increase in DNA labeling was observed in the P2 cells of the kidneys of the d-limonene-treated F344 rats, but no increase was observed in the d-limonene-treated NBR rats. A 10-fold increase in renal adenomas and atypical hyperplasia was found in the initiator-pretreated F344 rats that were dosed with d-limonene, but no increase was observed in the NBR rats treated with both the initiator and promotor. It is noteworthy that the incidence of nitrosamine- induced liver cancer in F344 rats decreased with d-limonene treatment (54.8% versus 86.7% treated with corn oil), which is consistent with the tumor suppres- sion activity observed by others (Crowell et al. 1994). The findings that d- limonene promoted preneoplastic lesions and renal tumors only in the presence of Î±2u-globulin and that this protein-limonene metabolite complex caused both the cytotoxic and the carcinogenic response in male rats led Dietrich and Swen- berg (1991) to conclude that extrapolation of d-limonene carcinogenicity data from rat studies to humans is probably not warranted. Another piece of data reported by Lehman-McKeeman and Caudill (1992) supports the conclusion that carcinogenesis induced by d-limonene in male rats is not relevant to humans for assessing risk of exposures to d-limonene. They found that d-limonen-1,2-oxide, a putative metabolite, binds to Î±2u-globulin (a lipocalin specifically synthesized in livers of male rats) but not to other lipocalin proteins found in other species, including human-derived Î±1-acid glycoprotein and human protein 1. The International Agency for Research on Cancer Working Group con- cluded that d-limonene produces renal tubular tumors in male rats by a non- DNA-reactive mechanism, through an Î±2u-globulin-associated response. There- fore, the mechanism by which d-limonene increases the incidence of renal tubu- lar tumors in male rats is not relevant to humans. d-Limonene is therefore not classifiable as carcinogenic to humans (IARC 1999). The Risk Assessment Fo- rum of the U.S. Environmental Protection Agency reached a similar conclusion that Î±2u-globulin-induced nephropathy in male rats would not be an appropriate end point to determine noncancer effects potentially occurring in humans (EPA 1991). The data on nephropathy and cancer in limonene-exposed male rats will not be used for setting exposure limits. Genetic Toxicology d-Limonene, tested at concentrations from 0.3 to 3,333 Âµg/plate, was found not to be mutagenic in four strains of Salmonella typhimurium (TA 98, TA 100, TA 1535, and TA 1537) in the presence or absence of liver metabolic enzymes (S9). Testing concentrations of d-limonene from 10 to 80 ÂµL/mL pro- duced negative results in a mouse L5178Y/TK+/â assay. At concentrations up to 100 ÂµL/mL, the compound did not induce sister-chromatid exchanges in the
264 SMACs for Selected Airborne Contaminants absence or presence of liver microsomes. Chromosomal aberrations were not observed in cultured Chinese hamster ovary cells treated with d-limonene at concentrations up to 162 ÂµL/mL (NTP 1990). Developmental and Reproductive Toxicity Two developmental studies were identified, as described below; however, no reproductive toxicity studies were found. In a developmental toxicity study of d-limonene in ICR mice, groups of 15 pregnant dams were gavaged with the compound at 0, 591, or 2,363 mg/kg/d on gestation days 7 to 12 (Kodama et al. 1977a). The high dose caused a significant decrease in maternal body weight; it also caused a significant increase in the number of fetuses with skeletal abnormalities, including lumbar ribs, fused ribs, and delayed ossification of several bones in the paws. No maternal or fetal ef- fects were observed at the low dose. Kodama et al. (1977b) also conducted a study on groups of 10 to 18 preg- nant Japanese white rabbits gavaged with d-limonene at 0, 250, 500, or 1,000 mg/kg/d on gestation days 6 to 18 (Kodama et al. 1977b). The dams that re- ceived the two highest doses had significant reductions in food consumption and body weight; death occurred in the group that received the highest dose. Devel- opmental toxicity in the litters was not observed at any dose. Allergenicity To demonstrate that the allergenicity of limonene is due to the oxidative products of limonene, Karlberg et al. (1992) stirred d-limonene (96% pure) in open air for 1 h four times daily for 2 to 4 h and up to 2 to 4 months to induce oxidative products (only 40% d-limonene was left after 2.5 months). Air- unexposed and air-exposed d-limonene together with d-limonene oxide were tested for skin allergenicity on guinea pigs; only d-limonene that had not been exposed to air was shown to be void of allergenicity. A skin sensitization test of d-limonene conducted on 25 volunteers was negative (Grief 1967). Two of 470 patients showed a positive response to a skin patch test carried out in Australia in 1999 (Fewings, personal communication, 2001, as cited in NICNAS 2002). A case report exists on asthma in subjects exposed to perfume containing d- limonene (Jensen and Petersen 1991). These data are insufficient to establish that d-d-limonene, per se, is an allergen and to quantitate a dose response; there- fore the data will not be used to calculate an acceptable concentration (AC). Effects on the Immune System The effects of d-limonene on the immune system of BALB/c mice were studied by Evans et al. (1987). They prepared the material in buffered saline as an emulsion and made a series of dilutions to attain a dilution as low as 1:16,384
Limonene 265 (no concentrations were given; doses were expressed as dilutions). At a dilution of 1:16,384 and with a daily dose of 0.1 mL per mouse, lipopolysaccharide- induced proliferation of spleen cells in mice was significantly suppressed after 4 wk of treatment, but proliferation increased significantly after 8 wk of treatment. This dilution also produced significant effects on concanavalin A responses, and on phytohemagglutinin-induced proliferation. It could be calculated that mice dosed with d-limonene at this dilution would receive 0.006 mg (or 6 Âµg) per mouse or a d-limonene concentration of 0.2 mg/kg/d. This dosage of d-limonene would be equivalent to a human drinking half a cup of orange juice daily. It seems unlikely that such a small amount of this low-toxicity compound has such immunologic effects in mice. Before conducting their immunologic study, Ev- ans et al (1987) conducted a dose-finding experiment for the study and reported a 50% lethal dose (LD50) of â0.080 mg d-limonene/kg (corrected for 82% pu- rity).â As stated above, the International Agency for Research on Cancer (IARC 1999) estimated human consumption of d-limonene to be 0.2 to 2 mg/kg/d (or 14 to 140 mg/70 kg/d); these values are greater than the lethal dose in Evansâs study. Vigushin et al. (1998) reported that cancer patients tolerated d-limonene at 189 mg/kg/d and showed no symptoms of toxicity. This human therapeutic dosage is 2,368 times higher than the mouse LD50 reported by Evan et al. In an NTP study involving large numbers of mice, no deaths or other sign of toxicity, other than decreased body weight gain, were observed in B6C3F1 mice exposed to d-limonene at 1,600 mg/kg/d for 16 days (NTP 1990). The dose in this NTP mouse study is 20,000 times higher than the Evans mouse LD50. The data of Evans are not consistent with the findings of others and should not be consid- ered for setting exposure limits. RATIONALE FOR ACCEPTABLE VALUES The American Industrial Hygiene Association (AIHA 1993) recommends a Workplace Environmental Exposure Level (WEEL) for d-limonene of 30 ppm. In providing the rationale for reaching this WEEL value, AIHA states that âin the 2-year NTP study, liver effects were noted in male mice at 500 mg/kg, and reduced survival was noted in female rats at 600 mg/kg. The no observable ef- fect levels (NOELs) were 250 and 300 mg/kg, respectively. A WEEL of 30 ppm (165.6 mg/m3) as an 8-h time-weighted average (TWA) is recommended to pro- tect against these effects.â No information is provided about how the WEEL, a recommended airborne concentration for humans, was derived from the rodent oral NOELs. The Threshold Limit Value (TLV) Committee of the American Confer- ence of Industrial Hygienists Association (ACGIH) has not set an occupational exposure limit on d-limonene. However, for sensory irritants, ACGIH recom- mends occupational exposure limits of 0.03 Ã RD50 based on mouse data (Cald- well 2002). This approach was initially proposed by Alarie (1981); he and his colleagues reported an RD50 for limonene in mice of 1,163 ppm, as previously
266 SMACs for Selected Airborne Contaminants discussed (Larsen et al., 2000), and proposed a TLV of 30 to 45 ppm, based on 0.03 Ã RD50. Several Nordic countries have occupational exposure limits on limonene of 25 to 75 ppm (see Table 13-6), but no rationales for these values could be found. RATIONALE FOR SMAC VALUES As mentioned above, d-limonene has a pleasant odor and dwarfs its levo- rotary isomer in the amount of industrial production and number of uses. If limonene is found in the spacecraft atmosphere, it is most likely to be the dex- trorotary isomer. Because toxicity studies on limonene have been conducted almost exclusively on d-limonene, the exposure limits, based on these data, are also for d-limonene. As also discussed above, d-limonene is one of the few compounds shown to induce a unique syndrome of nephropathy in male rats after subchronic or chronic exposure. After reviewing the literature on these effects of limonene and other hydrocarbons (EPA 1991), EPAâs Risk Assessment Forum concluded that nephropathy in male rats associated with Î±2u-globulin accumulation in hyaline droplets is not an appropriate end point to determine potential effects occurring in humans exposed to limonene. Therefore, the results for male rats would not be considered in setting exposure limits. Spacecraft maximum allowable con- centrations (SMACs) are derived by using relevant toxicologic data and following the guidelines developed by the Subcommittee on Guidelines for Developing Spacecraft Maximum Allowable Concentrations for Space Station Contaminants of the Committee on Toxicology (NRC 1992). The irritation study (Falk-Filipsson et al. 1993) conducted in humans exposed to limonene for 2 h was the longest inha- lation study on limonene and will be used to set the ACs for all lengths of time un- der consideration (1 h, 24 h, 7 d, 30 d, 180 d, and 1,000 d). Because there are no long inhalation exposure studies, the data on 13 wk and 2 yr histopathology gavage studies in rodents will be used to set ACs for exposures of 7 d and longer. The SMACs (Table 13-7) are chosen from the lowest AC at each time point summa- rized in Table 13-8. ACs Based on Short-Term Studies of Eye and Pulmonary Irritation and Human Test Subjects When eight human subjects engaged in light activity were exposed to d- limonene at concentrations up to 80 ppm (450 mg/mÂ³) for 2 h, no irritation or symptoms related to the central nervous system were noted. No changes in pul- monary function variables were detected (Falk-Filipsson et al. 1993). If limo- nene were to cause irritation, it would be the nonreactive type (Alarie, personal communication, 2004). Nonreactive irritation generally causes an effect that is
Limonene 267 TABLE 13-6 Limonene Occupational Exposure Limits Set, Recommended, or Proposed by Other Organizations Organization/Agency Limits, ppm Remarks Reference American Industrial 30 (168 mg/m3) 8-h WEEL TWAa AIHA 1993 Hygiene Association Swedish National Board of 25 (150 mg/m3) 8 hr TWA STELb SWEA 2005 Occupational Safety 50 (300 mg/m3) Danish Environmental 75 Occupational Madsen et al. 2001 Protection Agency exposure limit (tentative) Finnish Institute of 25 8-h TWA NICNAS 2002 Occupational Health Norway 25 8-h TWA RTECS 2006 a TWA, 8 h/d, 40 h/wk. b TWA for 15 min. TABLE 13-7 Spacecraft Maximum Allowable Concentrations for Limonenea Duration ppm mg/m3 Target Toxicity 1h 80 450 Eye and pulmonary irritation 24 h 80 450 Eye and pulmonary irritation 7d 20 115 Eye and pulmonary irritation 30 d 20 115 Eye and pulmonary irritation 180 d 20 115 Eye and pulmonary irritation 1,000 d 20 115 Eye and pulmonary irritation a Chosen from the lowest AC at each time point summarized in Table 13-8. relatively independent of exposure duration. According to Alarie, the maximum response to a nonreactive irritant will occur within the first 10 to 30 min of ex- posure (Nielson and Alarie 1982). Once this maximum is reached, the degree of irritation response is either maintained at this level or it gradually fades. This observation has been reported for many volatile compounds, including substi- tuted benzenes, alcohols, and pinenes tested by Alarieâs group (Kane et al. 1980, Nielson and Alarie 1982, Kasanen et al. 1998); especially relevant to the as- sessment of limonene is their study on pinenes. Pinenes, like limonene, are cy- clic monoterpenes. Falk-Filipsson showed that a 2-h exposure to 80 ppm of d- limonene did not cause irritation to the eyes and lungs, so it is valid to conclude that this concentration would not cause irritation at any given length of expo- sure. Therefore, 80 ppm is recommended as the AC for 1 and 24 h. However, the study was conducted in only eight human subjects; it is possible that sensi- .
TABLE 13-8 Acceptable Concentrations and Proposed SMACs for Limonene 268 Safety Factor for Exposure Extrapolation Acceptable Concentration, ppm Toxicity End Small size Points Exposure Data Species Time sample (n) 1 h 24 h 7 d 30 d 180 d 1,000 d No irritation in 8 human subjects exposed to 450 mg/m3 1 1 â(100/n) 80 80 20 20 20 20 human studya or 80 ppm experienced no irritation NOAEL in Rats (10 females) and mice (10 males, 10 10 1 or 2c -- -- -- 40 40 20 -- NTPâs 13-wk females) dosed at 500 and 600 mg/kg/d for toxicity studyb 13 wk showed no clinical signs or histopathology. The dose of 500 mg/kg/d is equivalent to an acceptable daily inhalation concentration of ~40 ppm for humans. NOAEL in Mice (male and female; 50/group) dosed for 10 1 -- -- -- -- -- 20 20 NTPâs 2-year 2 years with 250 or 300 mg/kg/d showed no toxicity and clinical signs or organ toxicity. A dose of carcino-genesis 250 mg/kg/d is equivalent to an acceptable bioassay.b daily inhalation concentration of ~20 ppm for humans. SMACsd 80 80 20 20 20 20 a Study of Falk-Filipsson et al (1993). b Study of NTP (1990). c See text for details. d Based on lowest acceptable concentrations. Abbreviation: NOAEL, no-observed-adverse-effect level; --, not calculated.
Limonene 269 tive individuals could find 80 ppm mildly irritating. Although mild irritation is acceptable for up to 24 h, for longer exposure durations (7, 30, and 180 d), it is necessary to ensure that limonene at the AC will not be irritating to essentially all crewmembers. According to the NRC guidelines (NRC 2000), a NOAEL for a large population could be derived from the NOAEL from a study involving a small number (N) of test subjects by incorporating a factor of â(100/N) (NRC 2000). Therefore, the acceptable limit of 20 ppm for long-term (7, 30, and 180 d) exposure is obtained as shown below. 1- and 24-h AC(eye and pulmonary irritation) = 80 ppm (NOAEL) 7-, 30-, and 180-d AC(eye and pulmonary irritation) = 80 ppm (NOAEL) Ã· â(100/8) (small n factor) = 22.6 ppm, rounded to 20 ppm 7-, 30-, and 180-d ACs Based on No-Observed-Adverse-Effect Level of NTP 13-wk Studies In the 13-wk NTP study (NTP 1990), at a dose of 1,200 mg/kg/d, d- limonene caused a decrease in activity, lethargy, and excessive lacrimation in rats. In mice, rough hair coat and decreased activity were observed at 1,000 mg/kg/d. Doses of 500 and 600 mg/kg/d produced no symptoms, thus, 500 mg/kg/d (the lower of these two doses) is considered a no-observed-adverse- effect-level (NOAEL). In order to extrapolate toxicity data from rodent to hu- man, a species-extrapolating factor of 10 is applied, making the NOAEL for humans 50 mg/kg/d. For a 70-kg person, this dose would be equivalent to 3,500 mg/d. Thus, 500 mg/kg/d (NOAEL) Ã 1/10 (species factor) Ã 70 kg = 3,500 mg/d. In order to use this 13-wk NTP gavage study data to extrapolate equivalent risk of inhalation exposure, two assumptions are made. The first is that a person would inhale 20 m3 of air per day (NRC 1992) and the second is that limonene uptake in the lung is 76%. This second assumption is based on results of the study by Falk-Filipsson et al. (1993), who reported that when two groups (eight per group) of human subjects were exposed to d-limonene at concentrations of 450 and 225 mg/mÂ³, the pulmonary uptake for each group was 68% Â± 4% (Mean + SD). The upper value of 76% (68% + 2 Ã SD or 68% + 8%), an estimate of the 95th percentile of the pulmonary uptake distribution, was used to calculate the AC. Thus, in order for a person to absorb 3,500 mg of limonene per day (human NOAEL), he or she would have to breathe air containing limonene at 230 mg/m3 for 24 h.
270 SMACs for Selected Airborne Contaminants The AC for 7 and 30 d is set at 230 mg/m3 or 40 ppm; the AC for 180 d is set at 115 mg/m3 or 20 ppm by applying a time factor of 2. The calculation is shown below: 3,500 mg/d (NOAEL) = 230 mg/m3 (equiv. inhal. conc.) Ã 20 m3/d (air inhal. rate) Ã 76% (pulmonary uptake) 7- and 30-d AC (eye and pulmonary irritation) = 230 mg/m3(equiv. inhal. conc.) Ã (0.18 ppm Ã· 1 mg/ m3) (conversion) = 41.4ppm, rounded to 40 ppm Because the NTP data came from a 13-wk (90-d) study, the AC for 180 d is obtained by applying a time-extrapolating factor of 2. 180-d AC (eye and pulmonary irritation) = 230 mg/m3 (equiv. inhal. conc.) Ã· 2 (time extrapolation factor) Ã (0.18 ppm Ã· 1 mg/ m3) (conversion) = 20.7 ppm, rounded to 20 ppm In the NTP studies, rodents were gavaged with bolus doses. As mentioned above, when humans and laboratory animals (rat, guinea pig, hamster, rabbit, and dog) were given oral doses of d-[14C]limonene, it was completely absorbed (Kodama et al. 1976). In a human inhalation study, the average pulmonary up- take of d-limonene vapor was 68%. Generally, systemic effects produced by a chemical given by bolus dose (in gavage) are more marked than those produced by an equivalent dose absorbed gradually from an inhalation exposure. In other words, an oral dose (x mg/kg) would likely be more toxic than an equivalent dose (x mg/kg) given by inhalation exposure. Therefore, the 3,500 mg/d of limonene absorbed into the body from inhalation exposure will have lower tox- icity than that given by gavage, and extrapolation of a gavaged dose to an inha- lation dose provides another safety margin. Similarly, at an equivalent amount of chemical absorbed from an expo- sure, a short-term exposure to a high concentration generally poses a greater toxicologic risk than a longer exposure to a lower concentration. Haberâs rule (c Ã t = k) is used to extrapolate data from a shorter exposure to a longer exposure but not the other way around. AC for 180-d Based on NOAEL of the NTP 2-Year Toxicology and Carcinogenesis Studies The noncarcinogenic results of the NTP 2-year toxicology and carcino- genesis studies showed that three groups of 50 male mice dosed with d-limonene at 0, 250, and 500 mg/kg/d and female mice dosed with d-limonene at 0, 500, and 1,000 mg/kg all had no compound-related clinical signs of toxicity. After week 28 of the study, the high-dose group of female mice had 5% to 15% lower mean body weights than the control group. In male mice, the incidence of multi-
Limonene 271 nucleated cells in the livers for the control, low-dose, and high-dose groups was 8/49, 4/36, and 32/50, respectively; the incidence of liver cytomegaly in these three groups followed the same pattern, with corresponding rates of 23/49, 11/36, and 38/50. Because the low-dose group showed less effect than the con- trol group, a benchmark dose approach was not used. Therefore, the NOAEL approach is used for AC setting. The mouse dose of 250 mg/kg/d was the NOAEL from the study. Applying a rodent-to-human extrapolation factor of 10 would provide an acceptable human oral exposure dose of 25 mg/kg/d (1,750 mg/70kg/d). Using an approach similar to the one used above for the 13-wk NTP study (pulmonary uptake of 76% and daily inhalation of 20 m3), we can calculate that a person breathing air containing 115 mg/m3 of limonene will ab- sorb 1,750 mg of limonene per day. The equivalent inhalation exposure concen- tration of 115 mg/m3 or 20 ppm is the AC for 180 d; the calculation is shown below: 1,750 mg/d (NOAEL) = 115 mg/m3 (equiv. inhal. conc.) Ã 20 m3/d (air inhal. rate) Ã 76% (pulmonary uptake) 180-d AC (carcinogenicity) = 115 mg/m3 (equiv. inhal. conc.) Ã (0.18 ppm Ã· 1 mg/ m3) (conversion) = 20.7 ppm, rounded to 20 ppm AC for 1,000-d Based on NOAEL of the NTP 2-Year Toxicology and Carcinogenesis Studies As discussed in the section on long-term toxicity studies and the preceding section, when groups of mice were gavaged with d-limonene at daily doses of 0, 250, and 500 mg/kg for 2 years, the incidence of multinucleated cells was 8/49, 4/36, and 32/50, respectively. The incidence of cytomegaly in these three groups followed the same non-dose-dependent pattern, with corresponding rates of 23/49, 11/36, and 38/50. No similar lesions were observed in rats exposed to 300 or 600 mg/kg/d. The chronic treatment dose of 250 mg/kg/d is considered a NOAEL. An acceptable human oral exposure dose of 25 mg/kg/d (1,750 mg/70kg/d) is obtained after applying a rodent-to-human extrapolation factor of 10. As calculated above, 25 mg/kg/d is equivalent to a daily inhalation exposure concentration of 115 mg/m3 or 20 ppm, which is chosen as the AC for 1,000 d. The 2 years (730 days) in the rodent bioassay study is about the lifetime of the mice and rats. For using data from the lifetime bioassay for setting a 1,000-d SMAC, the NRC SMAC committee agrees that no time factor would be needed. REFERENCES AIHA (American Industrial Hygiene Association). 1993. Workplace Environmental Ex- posure Level Guides on d-Limonene. American Industrial Hygiene Association, Fairfax, VA.
272 SMACs for Selected Airborne Contaminants Alarie, Y. 1981. Dose-response analysis in animal studies: Prediction of human re- sponses. Environ. Health Perspect. 42:9-13. Caldwell, D.J. 2002. Current Issues of Interest to the TLV-Chemical Substances Commit- tee. Forum 214: TLV Chemical Substances Committee: The Process for Decision Making, American Industrial Hygiene Conference and Exposition, June 1-6, 2002, San Diego, CA [online]. Available: http://www.acgih.org/tlv/CurrentIssuesTLVCS Comm.pps [accessed Oct. 7, 2004]. Crowell, P.L., C.E. Elson, H.H. Bailey, J.A. Elegbede, J.D. Haag, and M.N. Gould. 1994. Human metabolism of experimental cancer therapeutic agent d-limonene. Cancer Chemother. Pharmacol. 35(1):31-37. Dietrich, D.R., and J.A. Swenberg. 1991. NCI-Black-Reiter (NBR) male rats fail to de- velop renal disease following exposure to agents that induce alpha2u-globulin nephropathy. Fundam. Appl. Toxicol. 16(4):749-762. EPA (U.S. Environmental protection Agency). 1991. Alpha2u-Globulin: Association with Chemically-Induced Renal Toxicity and Neoplasia in the Male Rat. EPA/625/3-91/019F. Office of Health and Environmental Assessment, U.S. Envi- ronmental Protection Agency, Washington, DC. Evans, D.L., D.M. Miller, K.L. Jacobsen, and P.B. Bush. 1987. Modulation of immune responses in mice by d-limonene. J. Toxicol. Environ. Health 20(1-2):51-66. Falk, A., E. Gullstrand, A. LÃ¶f, and E. Wigaeus-Hjelm. 1990. Liquid/air partition coeffi- cients of four terpenes. Br. J. Ind. Med. 47(1):62-64. Falk-Filipsson, A., A. LÃ¶f, M. Hagberg, E.W. Hjelm, and Z. Wang. 1993. d-Limonene exposure to humans by inhalation: Uptake, distribution, elimination, and effects on the pulmonary function. J. Toxicol. Environ. Health 38(1):77-88. Gould, M.N. 1997. Cancer chemoprevention and therapy by monoterpenes. Environ. Health Perspect. 105(Suppl. 4):977-979. Grief, N. 1967. Cutaneous safety of fragrance material as measured by the Maximization test. Am. Perfumer Cosmetics 82:54-57 (as cited in NICNAS 2002). IARC (International Agency for Research on Cancer). 1999. d-Limonene. Pp. 307-328 in Some Chemicals that Cause Tumours of the Kidney or Urinary Bladder in Rodents and Some Other Substances: Summary of Data Reported and Evaluation, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 73. World Health Organization, International Agency for Research on Cancer [online]. Available: http://monographs.iarc.fr/ENG/Monographs/vol73/volume73.pdf [ac- cessed Oct. 7, 2004]. Igimi, H., M. Nishimura, R. Kodama, and H. Ide. 1974. Studies on the metabolism of d- limonene (p-mentha-1,8-diene). I. The absorption, distribution and excretion of d- limonene in rats. Xenobiotica 4(2):77-84. Igimi, H., T. Hisatsugu, and M. Nishimura. 1976. The use of d-limonene preparation as a dissolving agent of gallstones. Am. J. Dig. Dis. 21(11):926-939. Jensen, O.C., and I. Petersen. 1991. Occupational asthma caused by scented gravel in cat litter boxes [in Danish]. Ugeskr. Laeger. 153(13):939-940. JSC (Johnson Space Center). 2003. Analytical Results of ISS 11A, Lab Samples Re- turned on Soyuz 5 and STS-113 Container Air Samples. NASA Johnson Space Center Toxicology Group, Houston, TX [online]. Available: http://hefd.jsc.nasa. gov/files/STS113-ISS11Aconc.pdf [accessed July 9, 2008]. JSC (Johnson Space Center). 2008. Analytical Results of IE Grab Sample Container Air Samples. NASA Johnson Space Center Toxicology Group, Houston, TX [online]. Available: http://hefd.jsc.nasa.gov/files/Table_1B.1E_conc.xls [accessed July 9, 2008].
Limonene 273 Kane, L.E, R. Dombroske, and Y. Alarie. 1980. Evaluation of sensory irritation from some common industrial solvents. Am. Ind. Hyg. Assoc. J. 41(6):451-455. Kanerva, R.L., G.M. Ridder, F.R. Lefever, and C.L. Alden. 1987. Comparison of short- term renal effects due to oral administration of decalin or d-limonene in young adult male Fischer 344 rats. Food Chem. Toxicol. 25(5):345-353. Karlberg, A.T., K. Magnusson, and U. Nilsson. 1992. Air oxidation of d-limonene (the citrus solvent) creates potent allergens. Contact Dermatitis 26(5):332-340. Kasanen, J.P, A.L. Pasanen, P. Pasanen, J. Liesivuori, V.M. Kosma, and Y. Alarie. 1998. Stereospecificity of the sensory irritation receptor for nonreactive chemicals illus- trated by pinene enantiomers. Arch. Toxicol. 72(8):514-523. Kodama, R., T. Yano, K. Furukawa, K. Noda, and H. Ide. 1976. Studies on the metabo- lism of d-limonene (p-mentha-1,8-diene). IV. Isolation and characterization of new metabolites and species differences in metabolism. Xenobiotica 6(6):377-389. Kodama, R., A. Okubo, E. Araki, K. Noda, H. Ide, and T. Ikeda. 1977a. Studies on d- limonene as a gallstone solubilizer: VII. Effects on development of mouse fetuses and offsprings. Oyo Yakuri 13(6):863-873 (as cited in EPA 1993). Kodama, R., A. Okubo, K. Sato, E. Araki, K. Noda, H. Ide, and T. Ikeda. 1977b. Studies on d-limonene as a gallstone solubilizer: IX. Effects on development of rabbit fe- tuses and offsprings. Oyo Yakuri 13(6):885-898 (as cited in EPA 1993). Larsen, S.T., K.S. Hougaard, M. Hammer, Y. Alarie, P. Wolkoff, P.A. Clausen, C.K. Wilkins, and G.D. Nielsen. 2000. Effects of R-(+)- and S-(-)-limonene on the res- piratory tract in mice. Hum. Exp. Toxicol. 19(8):457-466. Lehman-McKeeman, L.D., and D. Caudill. 1992. Alpha 2u-globulin is the only member of the lipocalin protein superfamily that binds to hyaline droplet inducing agents. Toxicol. Appl. Pharmacol. 116(2):170-176. Lehman-McKeeman, L.D., P.A. Rodriguez, R. Takigiku, D. Caudill, and M.L. Fey. 1989. d-Limonene-induced male rat-specific nephrotoxicity: Evaluation of the associa- tion between d-limonene and alpha 2u-globulin. Toxicol. Appl. Pharmacol. 99(2):250-259. Madsen, T., H.B. Boyd, D. NylÃ©n, A.R. Pedersen, G.I. Petersen, and S. Flemming. 2001. Fragrances. Chapter 12 in Environmental and Health Assessment of Substances in Household Detergents and Cosmetic Detergent Products. Environmental Project 615. Danish Environmental Protection Agency, Denmark [online]. Available: http://www.mst.dk/udgiv/publications/2001/87-7944-596-9/html/kap12_eng.htm [acessed Oct. 7, 2004]. Molhave, L., S.K. Kjergaard, A. Hempel-Jorgensen, J.E. Juto, K. Andersson, G. Stridh, and J. Falk. 2000. The eye irritation and odor potencies of four terpenes which are major constituents of the emissions of VOCs from Nordic soft woods. Indoor Air 10(4):315-318. NICNAS (National Industrial Chemicals Notification and Assessment Scheme). 2002. Limonene. Priority Existing Chemical Assessment Report No. 22. National Indus- trial Chemicals Notification and Assessment Scheme, Commonwealth of Austra- lia. May 2002 [online]. Available: http://www.nicnas.gov.au/publications/car/pec/ pec22/pec_22_full_report_pdf.pdf [accessed Oct. 7, 2004]. Nielsen, G.D., and Y. Alarie. 1982. Sensory irritation, pulmonary irritation, and respira- tory stimulation by airborne benzene and alkylbenzenes: Prediction of safe indus- trial exposure levels and correlation with their thermodynamic properties. Toxicol. Appl. Pharmacol. 65(3):459-477.
274 SMACs for Selected Airborne Contaminants NRC (National Research Council). 1992. Guidelines for Developing Spacecraft Maxi- mum Allowable Concentrations for Space Station Contaminants. Washington, DC: National Academy Press. NRC (National Research Council). 2000. Methods for Developing Spacecraft Water Ex- posure Guidelines. Washington, DC: National Academy Press. NTP (National Toxicology Program). 1990. NTP Technical Report on the Toxicology and Carcinogenesis Studies of d-Limonene (CAS No. 5989-27-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies). Technical Report NTP TR 347. NIH 90-2802. National Toxicology Program, U.S. Department of Health and Human Services, National Institutes of Health, Research Triangle Park, NC [online]. Available: http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr347.pdf [accessed Apr. 18, 2008]. Opdyke, D.L. 1978. Monographs on fragrance raw materials: d-limonene. Food Cosmet. Toxicol. 16(Suppl. 1):809. Rohr, A.C., C.K. Wilkins, P.A. Clausen, M. Hammer, G.D. Nielsen, P. Wolkoff, and J.D. Spengler. 2002. Upper airway and pulmonary effects of oxidation products of (+)- alpha-pinene, d-limonene, and isoprene in BALB/c mice. Inhal. Toxicol. 14(7):663-684. RTECS (The Registry of Toxic Effects of Chemical Substances). 2006. p-Mentha-1,8- diene. RTECS No. OS8100000. CAS No. 138-86-3. The Registry of Toxic Effects of Chemical Substances, National Institute for Occupational Safety and Health [online]. Available: http://www.cdc.gov/niosh/rtecs/os7b98a0.html [accessed Apr. 18, 2008]. Saito, K., S. Uwagawa, H. Kaneko, and A. Yoshitake. 1991. Behavior of alpha 2u- globulin accumulating in kidneys of male rats treated with d-limonene: Kidney- type alpha 2u-globulin in the urine as a marker of d-limonene nephropathy. Toxi- cology 70(2):173-183. SWEA (Swedish Work Environment Authority). 2005. Occupational Exposure Limit Values and Measures against Air Contaminants. Statute Book. AFS 2005:17. Swedish Work Environment Authority, Solna, Sweden [online]. Available: http:// www.av.se/dokument/inenglish/legislations/eng0517.pdf [accessed Apr. 18, 2008]. Tsuji, M., Y. Fujisaki, Y. Arikawa, et al. 1975. Studies on d-limonene as a gallstone solubilizer. (III). Chronic toxicity in rats. Oyo Yakuri 9(3):403-412 (as cited in EPA 1993). Vigushin, D.M., G.K. Poon, A. Boddy, J. English, G.W. Halbert, C. Pagonis, M. Jarman, and R.C. Coombes. 1998. Phase I and pharmacokinetic study of D-limonene in pa- tients with advanced cancer. Cancer Chemother. Pharmacol. 42(2):111-117. Webb, D.R., R.L. Kanerva, D.K. Hysell, C.L. Alden, and L.D. Lehman-McKeeman. 1990. Assessment of the subchronic oral toxicity of d-limonene in dogs. Food Chem. Toxicol. 28(10):669-675. Wolkoff, P., P.A. Clausen, C.K. Wilkins, and G.D. Nielsen. 2000. Formation of strong airway irritants in terpene/ozone mixtures. Indoor Air 10(2):82-91.